|
Pfizer
Answers Critics with New Rx
During a meeting
with industry analysts, Pfizer said it intends to expand in
emerging markets. It also said that it will establish a new
business unit focusing on cancer drugs, and that it aims to
significantly boost the number of drugs in late-stage trials by
late next year. The company said it plans to seek 15–20
regulatory approvals between 2010 and 2012. Reuters
(3/5)
Can Pfizer Deliver a New
Prescription?
Though
Jeffrey Kindler took over Pfizer’s reins less than 2 years ago,
investors are becoming restless. Despite high expectations that
Kindler—who came in as a relative outsider—will revitalize the
company via fresh initiatives, Pfizer’s stock is down almost 15%
since he took over. The company will have to compensate for the
loss of about $13 billion of annual Lipitor (atorvastatin) revenue
when it goes off patent—perhaps as soon as 2010. The
Wall Street Journal (Subscription required) (3/4)
|
